

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office on the date shown below:

RESPONSE UNDER 37 CFR §1.111  
Examining Group 1617  
Patent Application  
Docket No. BB-117

March 26, 2008

David R. Saliwanchik  
David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Carlic K. Huynh  
Art Unit : 1617  
Applicants : Andreas Meisel *et al.*  
Serial No. : 10/506,598  
Filed : September 2, 2004  
Conf. No. : 1867  
For : Anti-infective Agents and/or Immunomodulators Used for Preventive Therapy Following an Acute Cerebrovascular Accident

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE UNDER 37 CFR §1.111

Sir:

A one month extension of time, through and including April 12, 2008, is being authorized with the electronic filing of this paper.

In response to the Office Action dated December 12, 2007, the following remarks are respectfully presented:

**Remarks/Arguments** begin on page 2 of this paper.